Quest Diagnostics Inc. (DGX): Price and Financial Metrics

Quest Diagnostics Inc. (DGX): $137.16

0.14 (-0.10%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

B

DGX Price/Volume Stats

Current price $137.16 52-week high $145.62
Prev. close $137.30 52-week low $119.59
Day low $135.82 Volume 132,626
Day high $138.00 Avg. volume 993,758
50-day MA $137.43 Dividend yield 2.18%
200-day MA $131.89 Market Cap 15.24B

DGX Stock Price Chart Interactive Chart >


Quest Diagnostics Inc. (DGX) Company Bio


Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United StatesPuerto RicoMexico, and Brazil.  Quest also maintains collaborative agreements with various hospitals and clinics across the globe. (Source:Wikipedia)


DGX Latest News Stream


Event/Time News Detail
Loading, please wait...

DGX Latest Social Stream


Loading social stream, please wait...

View Full DGX Social Stream

Latest DGX News From Around the Web

Below are the latest news stories about QUEST DIAGNOSTICS INC that investors may wish to consider to help them evaluate DGX as an investment opportunity.

Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare Conference

Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and President, and Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance, and the latest market developments and trends during a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024, at 6:45 p.m. Eastern Time.

Yahoo | December 21, 2023

Quest Diagnostics Names Yuri A. Fesko, M.D., Senior Vice President and Chief Medical Officer

Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that Yuri A. Fesko, M.D., has been named senior vice president and chief medical officer (CMO), effective immediately.

Yahoo | December 20, 2023

Quest Diagnostics (DGX) Unveils the 88-Compound NPS Test Panel

Quest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic.

Yahoo | December 20, 2023

Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis

Relationship leverages Quest's sequencing and specimen collection expertise with Scipher's precision medicine technology SECAUCUS, NJ and WALTHAM, MA / ACCESSWIRE / December 19, 2023 / Quest Diagnostics (NYSE:DGX), the world's leading provider of ...

Yahoo | December 19, 2023

Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel

Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives. Two of these classes are rapidly accelerating America's overdose crisis: other illi

Yahoo | December 19, 2023

Read More 'DGX' Stories Here

DGX Price Returns

1-mo -4.31%
3-mo 6.08%
6-mo 0.84%
1-year 0.53%
3-year 11.87%
5-year 49.06%
YTD 0.00%
2023 -10.05%
2022 -7.80%
2021 47.86%
2020 14.11%
2019 31.13%

DGX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full DGX Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!